程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习  

Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor

作　　者：夏涌[1] 寇晓霞[1] 杨喜晶[1] 周福平[1] 张迁[1] 钱其军[1] XIA Yong KOU Xiaoxia YANG Xijing ZHOU Fuping ZHANG Qian QIAN Qijun(Department of Bio-therapy, Eastern Hepatobiliary Surgical Hospital Affiliated to Second Military Medical University, Shanghai 201805 ,China)

机构地区：[1]第二军医大学附属东方肝胆外科医院生物治疗科,上海201805

出　　处：《药学实践杂志》2017年第2期174-177,共4页Journal of Pharmaceutical Practice

摘　　要：目的观察程序死亡受体1(programmed death-1,PD-1)抗体治疗晚期肿瘤患者的免疫疗效。方法选取东方肝胆外科医院生物治疗科2015年10月至2016年3月的18例晚期肿瘤患者,给予PD-1抗体静滴治疗。观察患者治疗前后的临床疗效、不良反应及无进展生存期,并对治疗前后患者的生活质量进行对比。结果患者经PD-1抗体治疗后,PR 5例、SD 7例、PD 6例,生活质量KPS评分较治疗前明显上升(P<0.05)。至随访结束,共有5例死亡,2例失访,11例存活,中位无进展生存期为2.6个月(95%CI:1.8~3.3个月),无严重不良反应和化验指标异常。结论 PD-1抗体是治疗晚期肿瘤安全有效的治疗方法,不良反应少,临床耐受良好,但该结论仍有待进一步大样本随机对照研究证实。Objective To observe the immune effect of PD1 （programmed death 1） antibody in the treatment of patients with advanced cancer. Methods From October 2015 to March 2016, 18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital. Clinical efficacy, adverse reactions and progression free survival time were monitored, The quality of life were compared before and after the treatment, Results Among 18 cases, PR 5 cases, SD 7 cases and PD 6 cases, The KPS scores for quality of life was significantly increased （P〈0.05） after treatment. At the end of follow-up, 5 patients died, 2 patients were lost in follow-up, 11 patients survived. The median progression free survival was 2.6 months （95 %CI： 1.8-3.3 months）. No serious adverse reactions and abnormal laboratory results were reported. Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors. It is well tolerated and has less adverse reactions. The randomized control studies with larger samples are needed to further confirm our conclusions.

关 键 词：PD-1抗体 晚期肿瘤 肿瘤免疫治疗 

分 类 号：R73[医药卫生—肿瘤]